Drug repurposing by in silico prediction of cyclizine derivatives as antihyperlipemic agents
Tóm tắt
Cardiovascular diseases are the primary factor for increased mortality rates around the world. Atherosclerosis brought on by high serum cholesterol can result in coronary heart disease (CHD). The risk of CHD is markedly reduced by lowering serum cholesterol levels. Scientists across the world are inventing new treatment regimens for lowering blood lipid levels. In this work, we repurposed the already established drugs, i.e., cyclizine derivatives as antihyperlipidemic agents. The repurposing was done based on the similarity of the selected cyclizine derivatives with the already established antihyperlipidemic drug, fenofibrate. Computational studies were performed and the 16 cyclizine derivatives docked against PPAR. alpha scored higher than fenofibrate. Lifarizine and medibazine outperform fenofibrate inmmgbsa. Fenofibrate, etodroxizine, meclizine, and cinnarizine had similar mmgbsa scores. The ADME properties of these compounds were performed and from that etodroxizine and levocetirizine were found to have better properties. The computational studies were performed using the Schrodinger software, maestro 12.8. The “Protein Preparation Wizard” module in the Maestro panel was used to create the protein structure and OPLS4 force field was used for energy minimization. The maestro builder panel’s “Ligprep”, “Receptor Grid Generation” and “Ligand Docking” modules were then used to prepare ligands, receptor grids and to perform docking respectively. MMGBSA was performed on the “prime MMGBSA” segment. Using the “Qikprop” setting in the maestro panel, a number of ADMET properties were predicted, and the program was run in default mode using vsgb as the solvation model.
Tài liệu tham khảo
Barbara A. Masters, Marshall J. Palmoski, Oliver P. Flint, Richard E. Gregg, David Wang-Iverson, Stephen K. Durham. In vitro mitotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin using neonatal rat skeletal myocytes.
"Cyclizine: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 01 Septmeber 2023.
Giulia Chinetti, Sophie Lestavel, Virginie Bocher, Alan T. Remaley , Bernadette Neve, Inés Pineda Torra, Elisabeth Teissier, Anne Minnich, Michael Jaye, Nicolas Duverger, H. Bryan Brewer, Jean-Charles Fruchart,Véronique Clavey , Bart Staels. (2001) PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nature Medicine 7 (1) 53.
Cronet P, Petersen JF, Folmer R, Blomberg N, Sjöblom K, Karlsson U, Lindstedt EL, Bamberg K (2001) Structure of the PPARα and -γ Ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9(8):699–706. https://doi.org/10.1016/s0969-2126(01)00634-7
Elisaf M (2002) Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 18(5):269–276
Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P, Shenkin PS (2004) Glide: a new approach for rapid, accurate docking and scoring 1. method and assessment of docking accuracy. J Med Chem 47(7):1739–1749. https://doi.org/10.1021/jm0306430
Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Current Controlled Trial Cardiovascular Med 2(5):205
Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA (2009) and Michael Christiansen. A Mutation Update. Human journal variation society, The Genetic Basis of Long QT and Short QT Syndromes
https://www.schrodinger.com/kb/1013
https://en.wikipedia.org/wiki/Cyclizine
Jacobson MP, Friesner RA, Xiang Z, Honig B (2002) On the role of the crystal environment in determining protein side-chain conformations. J Mol Biol 320(3):597–608
Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from monte carlo simulations. Bioorg Med Chem Lett 10:1155–1158
Jorgensen WL, Duffy EM (2002) Prediction of drug solubility from structure. Adv Drug Deliv Rev 54:355–366
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 23:3–25
Liu Z-M, Miao Hu, Chan P (2015) Brian Tomlinson Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opin Investig Drugs 24(5):611
Asmita Magotraa, Anjna Sharmaa , Samsher Singhb,c , Probir Kumar Ojhad , Sunil Kumarb,c , Naveen Bokoliac , Priya Wazira , Shweta Sharmae , Inshad Ali Khanc , Parvinder Pal Singhe , Ram A. Vishwakarmaf , Gurdarshan Singha, Utpal Nandia (2018) Physicochemical, pharmacokinetic, efficacy and toxicity profiling of a potential nitrofuranyl methyl piperazine derivative IIIM-MCD-211 for oral tuberculosis therapy via in-silico–in-vitro–in-vivo approach. Pulmonary Pharmacology and Therapeutics; 48 151–160.
Muhammad Ajmal Shaha,b , Wantana Reanmongkolc,d , Nisaudah Radenahmade , Ruqaiya Khalilf , Zaheer Ul-Haqf , Pharkphoom Panichayupakaranant. (2019) Anti-hyperglycemic and anti-hyperlipidemic effects of rhinacanthins-rich extract from Rhinacanthus nasutus leaves in nicotinamide-streptozotocin induced diabetic rats. Biomedicine and Pharmacotherapy.
Muhammad Tahir Aqeel, Nisar ur-Rahman, Arif-Ullah Khan, Zaman Ashraf, Muhammad Latif, Hummera Rafique, and Usman Rasheed. Antihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches. Drug design, development and therapy. 018:12 2443–2453.
Nandi S, Bagchi MC (2010) 3D-QSAR and molecular docking studies of 4-anilinoquinazoline derivatives: a rational approach to anticancer drug design. Mol Diversity 14:27–38
Nandi S, Bagchi MC (2011) In silico design of potent EGFR kinase inhibitors by structure based screening of combinatorial libraries. Mol Simul 37:196–209
Nandi S, Kumar M, Saxena M (2021) The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat COVID-19 utilizing structure-based molecular docking. Combinat Chem andHigh Throughput Screen 24(7):1055–1068
Ntie-Kang F (2013) An in silico evaluation of the ADMET profile of the StreptomeDB database. Springerplus 2:353
Packard CJ. (1998) Overview of fenofibrate. Eur Heart J. Suppl A A62–5. PMID: 9519345.
Patton KT, Thibodeau GA, (2010). Anatomy and Physiology (7th ed.). Mosby/ Elsevier. ISBN 978–9996057762.
Sudeep Pushpakom, Francesco Iorio, Patrick A. Eyers, K. Jane Escott, Shirley Hopper, Andrew Wells, Andrew Doig, Tim Guilliams, Joanna Latimer, Christine McNamee, Alan Norris, Philippe Sanseau, David Cavalla, Munir Pirmohamed. (2018) Drug repurposing: progress, challenges, and recommendations. Nature Reviews.
Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27(3):221–234. https://doi.org/10.1007/s10822-013-9644-8
Tuccinardi T (2021) What is the current value of MM/PBSA and MM/GBSA methods in drug discovery. Expert Opinion Drug Discovery. https://doi.org/10.1080/17460441.2021.1942836
Vandenberg JI, Walker BD, Campbell TJ (2001) HERG K+ channels: friend and foe. TRENDS Pharma Sci 22(5):240
Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-point binding free energy calculation with MM/PBSA and MM/ GBSA: strategies and applications in drug design. Chemical Rev. https://doi.org/10.1021/acs.chemrev.9b00055